Risk factors for damage accrual in primary antiphospholipid syndrome: A retrospective single-center cohort study

Ariela Hoxha1, Nicola Perin1, Marco Lovisotto1

  • 1Internal Medicine Unit, Thrombotic and Hemorrhagic Center, Department of Medicine, University of Padua, Italy.

Journal of Autoimmunity
|February 18, 2024
PubMed

Insights

Antiphospholipid syndrome (APS) patients frequently experience damage accrual, even with anticoagulant therapy. Microangiopathy and non-criteria manifestations significantly increase the risk of this damage.

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Antiphospholipid syndrome (APS) is associated with a high rate of recurrent events despite anticoagulant therapy.
  • These recurrent events can lead to significant damage accrual and diminished quality of life for patients.

Conclusions:

  • APS patients exhibit a higher frequency of damage accrual.
  • Microangiopathy and non-criteria manifestations are identified as independent risk factors for damage accrual in APS.
Abstract